Williams, James P.Hurst, JacobStöhr, WolfgangRobinson, NicolaBrown, HelenFisher, MartinKinloch, SabineCooper, David A.Schechter, MauroTambussi, GiuseppeFidler, SarahCarrington, MaryBabiker, AbdelWeber, JonathanKoelsch, Kersten K.Kelleher, Anthony D.Phillips, Rodney E.Frater, JohnMiró Meda, José M. (José María), 1956-Gatell, José M.SPARTAC Trial Investigators2017-11-022017-11-022014-09-122050-084Xhttps://hdl.handle.net/2445/117328In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.16 p.application/pdfengcc-by (c) Williams, James P. et al., 2014http://creativecommons.org/licenses/by/3.0/esVIH (Virus)AntiretroviralsMalalties infecciosesAssaigs clínicsHIV (Viruses)Antiretroviral agentsCommunicable diseasesClinical trialsinfo:eu-repo/semantics/article6491602017-11-02info:eu-repo/semantics/openAccess25217531